Gemini Therapeutics And Avitide Enter Into Exclusive License Agreement

“While antibodies have a relatively simple path through development, they are not non-antibody biopharmacies. We expected to meet the challenges and partnered with Avitide to disengage our lead program and accelerate preclinical development. Avitide has provided resins for process development, toxicological lot and cGMP manufacturing, in accordance with our CDMO time ranges. Given the success of our first partnership, we want to extend the relationship to other therapeutic programs in the Gemini portfolio,” said Scott Lauder, Chief Technology Officer of Gemini Therapeutics. The licensing agreement grants Gemini Therapeutics exclusive rights to certain Avitide affinity resins for preclinical, clinical and commercial manufacturing. In return, Avitide retains exclusivity for the manufacture and delivery of affinity resins to Gemini Therapeutics. “The development of biological processes is often on the critical path for every biopharmaceutical drug that arrives at the clinic; The introduction of an initial cleaning process that does not enter commercial manufacturing can result in significant costs and regulatory risks. Gemini recognized these risks from the beginning and decided to work with Avitide to jeopardize its entire development trajectory. We look forward to continuing our collaboration with Twins to bring this important therapy to the clinic,” said Kevin Isett, CEO of Avitide. About Avitide, Inc. Avitide has discovered, developed, produced and provides specific biopharmaceutical cleaning solutions and catalogs for the biopharmaceutical industry. Aviides proprieters AVIPure™-Affinity-Ligand-Portfolio sets the standard for precise affinity separations and consistent robust performance for its high-quality chromatographic products.

Avitide develops these technologies with a state-of-the-art 3-month concept for resin service that enables biopharmaceutical manufacturers and industrial developers to achieve faster schedules for bioprocessor product development, better process economy, predictable scalability and integrated continuous transformation of the next generation. The manufacture and supply of Avitide acaricide resins is carried out according to a quality management system according to ISO 9001:2015 and have been successfully tested on their quality systems and on the continuity of the supply plan for their affinity chromatography products. Avitide has successfully used affinity purification technologies for a number of biological molecules, including enzymes, bi-specific antibodies, therapeutic scaffolding, growth factors, hormones, insulins, blood factors, fc fusions, cell therapies, vaccines and viral gene therapy vectors. Avitide`s management team brings extensive sectoral know-how and a successful track record in the commercialization of innovative biopharmaceutical manufacturing platforms. Avitide is funded by leading private equity and private equity firms including Polaris Venture Partners, OrbiMed Advisors, Mithril Capital Management, Sands Capital Ventures, Section 32, SV Health Investors, Borealis Ventures and NeoMed Management. For more information, see www.avitide.com. About Gemini Therapeutics Gemini Therapeutics is a product engine company that focuses on redefining AMD and the link between disorders and precision medicine. Our candidates for eye therapy are adapted to molecular abnormalities in patients with high clinical need and our multimodal product engine has generated a rich pipeline with monoclonal antibodies, recombinant proteins and gene therapies.

With funding from leading life sciences investors and fueled by academic partnerships around the world, we are developing a number of first-class therapeutic drugs for retinal and complementary systemic diseases. For more information, see www.geminitherapeutics.com. LEBANON, N.H., Dec. 9, 2019 /PRNewswire/ — Avitide, Inc., the industry leader in the discovery and development of custom affinity cleaning resins, announces an exclusive licensing agreement to support the development of one of the pr